Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...

Highlights,Increased institutional ownership in Vertex Inc. with notable transactions recorded.,Strong year-over-year revenue ...

Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising ...

Did you just receive a form called a 1099-K ... vice president of The Tax Institute at H&R Block. Plenty of people. But most people didn't get a 1099-K in the past, Phillips said, because a ...

H.C. Wainwright raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $550 from $535 and keeps a Buy rating on the shares after the FDA approved Journavx for moderate-to-severe pain ...

LONDON — People in England with sickle cell disease will now be able to access the world’s first CRISPR-based medicine under a pricing and reimbursement agreement reached between U.K. health ...

The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals' Journavx for short-term pain that often follows surgery or injuries. It’s the first new pharmaceutical approach to ...

HOUSTON, January 22, 2025--(BUSINESS WIRE)--Vertex Energy, Inc. ("Vertex" or the "Company"), a leading specialty refiner and marketer of high-quality refined products, together with its affiliates ...